Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERA study: Intravenous Trastuzumab in HER2-Positive Primary Breast Cancer
jRCT2080220185Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of trastuzumab in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220185.